GlassScriptPhysician profile
Brooke B Halpern
NPI 1184158248
$12,210.89
in general payments reported to CMS, 2019-2025
69 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $560 · 2021: $2,051 · 2022: $2,002 · 2023: $2,477 · 2024: $2,394 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,991 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,990.62 |
| Education | $104.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,845.71 | 2021-2025 | |
| Novo Nordisk INC | $1,232.56 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,040.09 | 2019-2025 | |
| Amgen INC. | $1,031.63 | 2019-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $688.76 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $531.61 | 2021-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $481.29 | 2021-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $449.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $321.58 | 2020-2025 | Rexulti, Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.68 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $268.78 | 2021-2025 | Spravato, Xarelto |
| Dexcom, INC. | $251.38 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $242.90 | 2021-2025 | Verquvo, Steglatro, Januvia |
| Glaxosmithkline, LLC. | $235.60 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $226.57 | 2020-2025 | Airsupra, Breztri, Farxiga |
Show all 68 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Halpern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.